ライフサイエンスコーパス: pregnancy outcome

1 embolic and bleeding complications, HIT, and pregnancy outcome).

2 in 71% of the women, with no relationship to pregnancy outcome.

3 this histiotrophic pathway leads to adverse pregnancy outcome.

4 parameters at 20 and 32 weeks gestation, and pregnancy outcome.

5 ened or tested for syphilis; (2) reported on pregnancy outcome.

6 D in poly(I:C)-treated WT mice led to normal pregnancy outcome.

7 LMWH but produce little or no improvement in pregnancy outcome.

8 nt mortality to 12 weeks (84 days) following pregnancy outcome.

9 ze the in vivo effects of Nod1 activation on pregnancy outcome.

10 nsumption was not associated with an adverse pregnancy outcome.

11 n retarded fetal development and compromised pregnancy outcome.

12 ive cohort study of maternal oral health and pregnancy outcome.

13 TE) Study and to determine associations with pregnancy outcome.

14 ge is a common and poorly understood adverse pregnancy outcome.

15 nal-fetal interface and this could influence pregnancy outcome.

16 mplicated in periodontal disease and adverse pregnancy outcome.

17 res of EVT cells that can be correlated with pregnancy outcome.

18 evention of complications and improvement of pregnancy outcome.

19 new drug targets against associated adverse pregnancy outcome.

20 the maternal-fetal interface for successful pregnancy outcome.

21 ydrogen sulfide donors are likely to improve pregnancy outcomes.

22 dvice with healthy eating advice on selected pregnancy outcomes.

23 dontal diseases are risk factors for adverse pregnancy outcomes.

24 iome may influence susceptibility to adverse pregnancy outcomes.

25 ss all three trimesters of pregnancy affects pregnancy outcomes.

26 armaceutical intervention to prevent adverse pregnancy outcomes.

27 phenol concentrations with reproduction and pregnancy outcomes.

28 These infections were associated with poor pregnancy outcomes.

29 ations were not associated with most adverse pregnancy outcomes.

30 diating maternal-fetal infection and adverse pregnancy outcomes.

31 ects of LGI dietary advice with HE advice on pregnancy outcomes.

32 vicular fluid (GCF) and serum cytokines, and pregnancy outcomes.

33 including letrozole, might result in better pregnancy outcomes.

34 and acquired TTP have assisted in excellent pregnancy outcomes.

35 P = 0.723), or other metabolic variables or pregnancy outcomes.

36 man immunodeficiency virus, and from adverse pregnancy outcomes.

37 associated with adverse maternal or neonatal pregnancy outcomes.

38 ic for induced Foxp3 expression, with normal pregnancy outcomes.

39 exert additional, maladaptive influences on pregnancy outcomes.

40 bacteria, potentially giving rise to adverse pregnancy outcomes.

41 ly to increase statistical power for testing pregnancy outcomes.

42 ternal-fetal interface, resulting in adverse pregnancy outcomes.

43 reported childhood development or growth or pregnancy outcomes.

44 fonate (PFOS) may be associated with adverse pregnancy outcomes.

45 at treatment does not alter rates of adverse pregnancy outcomes.

46 ternal stress during pregnancy may influence pregnancy outcomes.

47 l periodontitis during pregnancy and adverse pregnancy outcomes.

48 arch midwives throughout follow-up to assess pregnancy outcomes.

49 r parasite antigens associated with improved pregnancy outcomes.

50 ychiatric disease is associated with adverse pregnancy outcomes.

51 ciated malaria (PAM) is associated with poor pregnancy outcomes.

52 anisms responsible for air pollution-related pregnancy outcomes.

53 e associated with increased risks of adverse pregnancy outcomes.

54 uated between cancer treatments and untoward pregnancy outcomes.

55 rs in general, increase the risk for adverse pregnancy outcomes.

56 l function and how it may contribute to poor pregnancy outcomes.

57 dose pelvic irradiation and specific adverse pregnancy outcomes.

58 escribed treatments on the risks of non-live pregnancy outcomes.

59 ious observations relating IFN-gamma to poor pregnancy outcomes.

60 Patients were categorized according to final pregnancy outcomes.

61 r diseases have been associated with adverse pregnancy outcomes.

62 eters, testicular sperm retrieval rates, and pregnancy outcomes.

63 ic factors have been associated with adverse pregnancy outcomes.

64 s, plaque and gingivitis scores, and current pregnancy outcomes.

65 regnant women and is associated with adverse pregnancy outcomes.

66 nt air pollutants is associated with adverse pregnancy outcomes.

67 lic adaptations are essential for successful pregnancy outcomes.

68 tion between periodontal disease and adverse pregnancy outcomes.

69 utrient-poor diets and to experience adverse pregnancy outcomes.

70 associated with low birth weight and adverse pregnancy outcomes.

71 mild gestational diabetes mellitus improves pregnancy outcomes.

72 ry were associated with malaria-related poor pregnancy outcomes.

73 responses and may be associated with adverse pregnancy outcomes.

74 transmission (MTCT) of HIV and other adverse pregnancy outcomes.

75 s associated with increased risks of adverse pregnancy outcomes.

76 ulatory functions in female reproductive and pregnancy outcomes.

77 their symptomatology, and that may influence pregnancy outcomes.

78 ollow-up is conducted to obtain and classify pregnancy outcomes.

79 nducted to evaluate effects on fertility and pregnancy outcomes.

80 rticularly when active, can adversely affect pregnancy outcomes.

81 the first antenatal visit, and these improve pregnancy outcomes.

82 luding autoimmune diseases, malignancies and pregnancy outcomes.

83 low birthweight were the most common adverse pregnancy outcomes.

84 l syphilis infections caused 520 000 adverse pregnancy outcomes.

85 associated with an increased risk of adverse pregnancy outcomes.

86 placenta but was not previously analyzed in pregnancy outcomes.

87 they thought were most important to improve pregnancy outcomes.

88 in patients at an increased risk of adverse pregnancy outcomes.

89 attachment, leading to severely compromised pregnancy outcomes.

90 little is known about its ability to improve pregnancy outcomes.

91 -vitro studies, and studies without data for pregnancy outcomes.

92 ain how Ct infection could result in adverse pregnancy outcomes.

93 meta-analysis to verify the effect of AH on pregnancy outcomes.

94 l weight gain is associated with unfavorable pregnancy outcomes.

95 on have shown mixed results and lack data on pregnancy outcomes.

96 ween the vaginal microbiome, host health and pregnancy outcomes.

97 rum parasitemia during pregnancy on multiple pregnancy outcomes.

98 d beneficial effects on metabolic status and pregnancy outcomes.

99 ever be associated with adverse maternal and pregnancy outcomes.

100 nts were conscious of its negative impact on pregnancy outcomes.

101 educe the risk of multiple birth and adverse pregnancy outcomes after in-vitro fertilisation (IVF).

102 Individual-level epidemiologic studies of pregnancy outcomes after maternal influenza are limited

103 early pregnancy have high risks of non-live pregnancy outcomes, although the contribution of the und

104 intelligence, gross development, growth, or pregnancy outcomes, although there was an improvement in

105 ation of nutritional indicators with adverse pregnancy outcomes among HIV-infected women in Tanzania,

106 significantly decreased the risk of adverse pregnancy outcomes among HIV-infected women.

107 of the RDA in decreasing the risk of adverse pregnancy outcomes among HIV-infected women.

108 tiple RDAs on decreasing the risk of adverse pregnancy outcomes among HIV-infected women.

109 rvational prospective cohort study to assess pregnancy outcomes among HIV-positive women in Ukraine.

110 Pregnancy outcome and BC-pregnancy interval did not seem

111 Subgroup analyses included DFS according to pregnancy outcome and BC-pregnancy interval.

112 The link between pregnancy outcome and future CVD risk is now better unde

113 Pregnancy outcome and maternal/infant ART were collected

114 We assessed the impact of the acute event on pregnancy outcome and on neonatal complications, such as

115 iparum could have important consequences for pregnancy outcome and responses to P. falciparum infecti

116 Secondary outcomes included pregnancy outcome and thyroid function.

117 n trial in Tanzania were monitored to assess pregnancy outcomes and child mortality.

118 have been linked to a wide range of adverse pregnancy outcomes and could possibly influence birth we

119 Secondary end points included pregnancy outcomes and disease-free and overall survival

120 of pregnancy are not associated with adverse pregnancy outcomes and do not predict complications any

121 f pregnancy and its association with adverse pregnancy outcomes and examined the predictive accuracy.

122 Importantly, USPIO did not affect pregnancy outcomes and liver function in the mother and

123 assess the home visiting program's effect on pregnancy outcomes and maternal and child health through

124 nvestigate the relationships between adverse pregnancy outcomes and modifiable risk factors for cardi

125 possible effect on the incidence of adverse pregnancy outcomes and MTCT of HIV.

126 t studies suggest both novel markers of poor pregnancy outcomes and new approaches to the management

127 ty that unlocks new strategies for improving pregnancy outcomes and novel approaches for therapeutica

128 is that combined the epidemiology on adverse pregnancy outcomes and other health effects with long-te

129 e determined and tested for association with pregnancy outcomes and PAM indicators using linear and l

130 sed to assess the impact of PI-based cART on pregnancy outcomes and progesterone levels in vivo.

131 Improved recording of all pregnancy outcomes and standard application of preterm d

132 the impact of periodontal disease on adverse pregnancy outcomes and to identify potential underpinnin

133 rable to iron deficiency and related adverse pregnancy outcomes and, as such, are routinely recommend

134 epth of phenotypic information about adverse pregnancy outcomes, and clinical data and biospecimens f

135 haracteristics, treatment variables, adverse pregnancy outcomes, and internal validity quality criter

136 e linked information on vaccination, adverse pregnancy outcomes, and potential confounders among wome

137 equestered parasites is associated with poor pregnancy outcomes, and protection may be mediated in pa

138 ndness, higher child mortality, anemia, poor pregnancy outcomes, and reduced work capacity.

139 ring pregnancy and may contribute to adverse pregnancy outcomes (APOs).

140 between periodontal disease (PD) and adverse pregnancy outcomes (APOs).

141 Treatments to improve pregnancy outcomes are being studied.

142 Recruitment and pregnancy outcomes are complete but childhood follow-up

143 c background is a critical factor in adverse pregnancy outcome as sequela to U. parvum intra-amniotic

144 Using these levels in studies of pregnancy outcomes, as nicely illustrated by the study o

145 effect on weight, nutritional outcomes, and pregnancy outcomes, as well as its effect on progression

146 We assessed adverse pregnancy outcomes associated with ART initiated before

147 all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before

148 haps be involved in the induction of adverse pregnancy outcomes associated with long-term consumption

149 g limited validity to assess drug safety for pregnancy outcomes associated with prematurity.

150 mprove the ability to predict severe adverse pregnancy outcomes (AUC: 0.64; likelihood ratio: 2.32; P

151 both sexes, and, in women, with abortion and pregnancy outcome before 18 years of age.

152 s of age with labor and delivery or abortive pregnancy outcome between 2005 and 2013.

153 no differences in the prevalence of adverse pregnancy outcomes between groups.

154 ed with increased mortality rate and adverse pregnancy outcome, but little is known about offspring m

155 fficiency lead to maternal and fetal adverse pregnancy outcome, but their pathologic mechanisms are u

156 y did not improve HIV disease progression or pregnancy outcomes, but may improve child survival.

157 acid (PFOA) is a potential cause of adverse pregnancy outcomes, but previous studies have been limit

158 toxins by intensified hemodialysis improves pregnancy outcomes, but small numbers and the absence of

159 ly but independently associated with adverse pregnancy outcomes, but the findings are impacted by per

160 is associated with increased risk of adverse pregnancy outcomes, but the mechanisms are unknown.

161 ted low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been ad

162 unosuppression do not adversely affect their pregnancy outcomes compared with adult-tx mothers.

163 g, treatment, or adverse effect studies with pregnancy outcome data in women who are asymptomatic for

164 Many adverse pregnancy outcomes differ by race.

165 e is a substantial increased risk of adverse pregnancy outcomes due to leflunomide exposure among wom

166 are potentially at increased risk of adverse pregnancy outcomes, due to a range of factors, including

167 Reliable data are lacking on pregnancy outcomes during Ebola virus disease (EVD) epid

168 dose response between dialysis intensity and pregnancy outcomes emerged, with live birth rates of 48%

169 maternal syphilis caused substantial adverse pregnancy outcomes, even in women receiving antenatal ca

170 pport for an effect of PFOA exposure on most pregnancy outcomes, except for early preterm birth and p

171 nal, placental, and fetal viral infection to pregnancy outcome, fetal development, and maternal well-

172 There are very little data available on pregnancy outcomes following antenatal exposure to other

173 We analyzed pregnancy outcomes following recovery from TTP associate

174 Pregnancy outcomes for child-tx mothers are similar to t

175 Pregnancy outcomes for women who received a kidney trans

176 The incidence of pregnancy outcomes for women with the purely obstetric f

177 We compared pregnancy outcomes from 22 pregnancies in the Toronto Pr

178 knowledge of CDC-accredited 25(OH)D data and pregnancy outcomes from a large, clinically validated, p

179 stage 1 CKD remained associated with adverse pregnancy outcomes (general combined outcome) in women w

180 efined by GDM [the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study] or were identified as ch

181 diopulmonary exercise testing parameters and pregnancy outcome has not been defined.

182 link between periodontal disease and adverse pregnancy outcome have gone through several phases.

183 Associations between vitamin D and pregnancy outcomes have been inconsistent.

184 drinking water disinfection by-products and pregnancy outcomes have been limited by the complexity o

185 anges such as impaired fertility and adverse pregnancy outcomes have been related to female asthma.

186 pproaches for analyzing the risks of adverse pregnancy outcomes have been the source of much debate a

187 ified a new mechanism by which LMWH improves pregnancy outcome in a murine model of factor V Leiden t

188 ional deletion of uterine Trp53 and examined pregnancy outcome in females with this genotype.

189 rooctane sulfonate (PFOS) with self-reported pregnancy outcome in Mid-Ohio Valley residents (2000-200

190 Pregnancy outcome in patients with ICP (N = 307) was stu

191 , causing localized inflammation and adverse pregnancy outcome in the presence or absence of clinical

192 The objective of this study was to assess pregnancy outcome in women with a history of refractory

193 diovascular parameters to UDF parameters and pregnancy outcome in women with CHD.

194 tested as an experimental drug for improving pregnancy outcome in women with inherited thrombophilia

195 am the biochemical, obstetric management and pregnancy outcome in women with intrahepatic cholestasis

196 known to carry an increased risk of adverse pregnancy outcome in women without overt diabetes.

197 pectively investigated 27 maternal and fetal pregnancy outcomes in 14 women with aHUS from the Vienna

198 pregnancy have been associated with adverse pregnancy outcomes in a few studies but not in other stu

199 udy were to investigate invasion and adverse pregnancy outcomes in gerbils orally exposed to L. monoc

200 morbidity, HIV disease progression, and poor pregnancy outcomes in HIV-infected women.

201 y of which have been associated with adverse pregnancy outcomes in humans although their sources of i

202 sium supplementation on metabolic status and pregnancy outcomes in magnesium-deficient pregnant women

203 sium supplementation on metabolic status and pregnancy outcomes in maternal-child dyads affected by g

204 Statins have been linked to improved pregnancy outcomes in mouse models of PE and APS, possib

205 ime, metformin should not be used to improve pregnancy outcomes in obese women without diabetes.

206 l fasting glucose, the metabolic profile, or pregnancy outcomes in obese women.

207 denafil did not prolong pregnancy or improve pregnancy outcomes in severe early-onset fetal growth re

208 Pregnancy outcomes in SSRI users were compared with thos

209 rsely affect successful conception and early pregnancy outcomes in the first and second trimester (<2

210 We describe challenges in studying adverse pregnancy outcomes in the setting of observational resea

211 around 2-4%, but little is known about other pregnancy outcomes in this setting.

212 Monitoring of pregnancy outcomes in Ukraine will be important as use o

213 rombotic thrombocytopenic purpura (TTP), but pregnancy outcomes in women who have recovered from acqu

214 present study was undertaken to investigate pregnancy outcomes in women who received leflunomide and

215 hronotropic response correlates with adverse pregnancy outcomes in women with congenital heart diseas

216 The incidence of pregnancy outcomes in women with constitutive thrombophi

217 We compared pregnancy outcomes in women with r-AKI without history o

218 study suggests that pravastatin may improve pregnancy outcomes in women with refractory obstetric AP

219 havior; poor coping strategies; and negative pregnancy outcomes in women, although evidence about the

220 Pregnancy outcomes included small-for-gestational age (S

221 l syphilis infections caused 350 000 adverse pregnancy outcomes including 143 000 early fetal deaths

222 Pregnancy outcomes including live birth rates, gestation

223 reproductive health surveys among refugees; pregnancy outcomes, including abortion, maternal mortali

224 were both at increased risk of many adverse pregnancy outcomes, including cesarean section and need

225 etween maternal vitamin D status and adverse pregnancy outcomes, including low birth weight and prete

226 reased risk of systemic diseases and adverse pregnancy outcomes, including pregnancy hypertension (PH

227 tial link between maternal periodontitis and pregnancy outcomes, including preterm birth (<37 weeks)

228 identified several novel predictors of poor pregnancy outcomes, including uterine Doppler and labora

229 nancy weight gain and adverse or physiologic pregnancy outcomes independent of gestational age.

230 Pregnancy outcome is severely compromised by intrauterin

231 urther investigation of these differences in pregnancy outcomes is a public health priority.

232 S), we assessed whether the risk for adverse pregnancy outcomes is associated with CKD by comparing p

233 e periconception HIV risk, but the effect on pregnancy outcomes is not well defined.

234 common during pregnancy but their impact on pregnancy outcomes is unclear.

235 f clinically recovered AKI (r-AKI) on future pregnancy outcomes is unknown.

236 Prediction, largely based on prior pregnancy outcomes, is not possible in women pregnant fo

237 sely, but given the low incidence of adverse pregnancy outcomes, large populations must be studied.

238 tions have also been associated with adverse pregnancy outcomes; limited data have suggested that the

239 xygenase-2 in the females with these adverse pregnancy outcomes, may be related to a subclinical proi

240 Temperature-related effects on pregnancy outcomes merit additional investigation.

241 late oral inflammatory load (OIL) to adverse pregnancy outcomes more precisely, but given the low inc

242 unomodulator and may protect against adverse pregnancy outcomes, mother-to-child transmission (MTCT)

243 amniotic fluid samples of women with normal pregnancy outcomes (n = 28) and women with (n = 39) and

244 pilepsy and antiepileptic drug exposure with pregnancy outcomes needs to be quantified to guide manag

245 Adverse pregnancy outcomes occurred only in the dams treated wit

246 and Cardiac disease (ROPAC), we describe the pregnancy outcome of 212 patients with an MHV.

247 hood ratio for a composite of severe adverse pregnancy outcomes of 25(OH)D concentrations <25 nmol/L

248 outcomes is associated with CKD by comparing pregnancy outcomes of 504 pregnancies in women with CKD

249 s prior to conception significantly affected pregnancy outcomes of female rats, with respect to deliv

250 Pregnancy outcomes of perinatally human immunodeficiency

251 These results suggest that the adverse pregnancy outcomes of preterm birth, PPROM, placental ab

252 xperienced by one generation that affect the pregnancy outcomes of the next generation.

253 ing pregnancy, concerns about the effects on pregnancy outcome often arise.

254 re responsible for some instances of adverse pregnancy outcome or developmental disease, gene-environ

255 MR was not associated with increased adverse pregnancy outcomes or augmented risk of malaria in the i

256 Whether these effects have benefits for pregnancy outcomes or early childhood requires additiona

257 either trial in any other neurocognitive or pregnancy outcomes or in the incidence of adverse events

258 HbAC and HbAS were not associated with other pregnancy outcomes or PAM indicators.

259 mbosis, thrombophilia, and a history of poor pregnancy outcome, or risk factors for postpartum thromb

260 The Pregnancy Outcome Prediction (POP) study was a prospecti

261 the effects of disease activity, we examined pregnancy outcomes (preterm birth, stillbirth, small for

262 o reverse causality by correlates of adverse pregnancy outcomes, reflective of the chemicals of inter

263 he greatest increased risks for all non-live pregnancy outcomes, relative to those with no history of

264 Biomarkers for these adverse pregnancy outcomes remain elusive.

265 ever, its effects within the placenta and on pregnancy outcomes remain largely unknown.

266 a, including cardiovascular disease, adverse pregnancy outcomes, rheumatoid arthritis, inflammatory b

267 about environmental contaminants and adverse pregnancy outcomes should be designed to elucidate poten

268 tween low 25(OH)D concentrations and adverse pregnancy outcomes (small for gestational age, preterm b

269 gestational weight gain (GWG) and 5 adverse pregnancy outcomes (small-for-gestational-age (SGA) birt

270 ic groups from the Hyperglycemia and Adverse Pregnancy Outcome Study.

271 ' gestation in the Hyperglycemia and Adverse Pregnancy Outcome Study.

272 d Health and Human Development's Nulliparous Pregnancy Outcomes Study-Monitoring Mothers-to-Be (nuMoM

273 f biomass fuels has been linked with adverse pregnancy outcomes such as low birth weight, stillbirth,

274 HG has been associated with adverse pregnancy outcomes such as low birth weight.

275 Adverse pregnancy outcomes, such as preterm birth, preeclampsia

276 uenza vaccination might also prevent adverse pregnancy outcomes, such as preterm birth.

277 od-borne pathogen that can result in adverse pregnancy outcomes, such as stillbirth or premature deli

278 with a significantly higher risk of adverse pregnancy outcomes than no such exposure.

279 o immigrate to the United States have better pregnancy outcomes than their US-born counterparts.

280 during pregnancy is associated with adverse pregnancy outcomes that are known to be more prevalent i

281 profile compared with valproate for adverse pregnancy outcomes, the requirements for seizure control

282 arison were obtained from women with healthy pregnancy outcome through UKOSS (n = 2,232), St Mary's M

283 rtant implications for infection and adverse pregnancy outcomes throughout gestation and should be of

284 the vaginal microbiome and its influence on pregnancy outcome varies with pregnancy history.

285 Information about pregnancy outcomes was obtained from medical records.

286 dary autoimmunity, malignancy and death, and pregnancy outcomes was recorded.

287 ng IVF to investigate human reproduction and pregnancy outcomes, we found that concentrations of some

288 By studying the risk of untoward pregnancy outcomes, we indirectly assessed the risk of t

289 a prospective study of its association with pregnancy outcomes, we used a compromised approach using

290 malaria exposure, HIV infection status, and pregnancy outcomes were assessed.

291 Some risk factors for adverse pregnancy outcomes were directly associated with HIV and

292 Laboratory test results and pregnancy outcomes were evaluated for a subgroup of preg

293 environmental determinants of fertility and pregnancy outcomes were included.

294 diabetes, cardiovascular disease and adverse pregnancy outcomes were not discussed by working group 4

295 en mother and infant in the risks of adverse pregnancy outcomes were reached at lower gestational wei

296 Pregnancy outcomes were recorded at parturition.

297 s globally, monitoring for potential adverse pregnancy outcomes will be crucial.

298 Stillbirth is a common adverse pregnancy outcome, with nearly 3 million third-trimester

299 effects of the mother and fetal membranes on pregnancy outcome, with possible implications for choles

300 recapitulates many features of human adverse pregnancy outcome, with pregnancies characterized by fet